Inactive Instrument

Teligent

Equities

TLGT

US87960W2035

IGI, Laboratories, Inc. Completes Filing of Two Product Development ANDAs with the FDA

January 04, 2013 at 01:00 pm

IGI, Laboratories, Inc. announced that it filed two abbreviated new drug applications, or ANDAs, on December 28 and December 31, 2012 in accordance with one of its customer development agreements. The company executed the customer development agreement earlier in 2012, and completed the development of the two topical generic drug products and filing of the related ANDAs by year end. Upon FDA approval, the company will manufacture and package the products in the customer's label.

Latest news about Teligent

Teligent, Inc. Went Out of Business	26/07/22	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	15/07/22	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	25/05/22	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	24/05/22	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	29/04/22	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	27/04/22	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	08/04/22	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	01/03/22	CI
Motion for Case Conversion Filed by Teligent, Inc.	23/02/22	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	10/02/22	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	03/02/22	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	02/02/22	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	02/02/22	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/01/22	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/01/22	CI
Motion for Asset Sale Approved for Teligent, Inc.	19/01/22	CI
London Shares to Open Higher as Traders Focus On Key Data	17/01/22	DJ
Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition	17/01/22	MT
Asset Purchase Agreement Filed by Teligent, Inc.	17/01/22	CI
Asset Purchase Agreement Filed by Teligent, Inc.	17/01/22	CI
Asset Purchase Agreement Filed by Teligent, Inc.	17/01/22	CI
Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.	16/01/22	CI
Notice of Selection of Successful Filed for Teligent, Inc.	14/01/22	CI
Notice of Selection of Successful Filed for Teligent, Inc.	14/01/22	CI
Notice of Selection of Successful Filed for Teligent, Inc.	14/01/22	CI

Chart Teligent

Duration

Period

More charts

Company Profile

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company